News & Events
This will take effect December 16, 2013
Overview and Clinical Utility:
Effective December 16, 2013, PathGroup will switch the current Group B Strep Detection by PCR assay to a new platform. The new assay will be the FDA-approved BD MAX™ GBS. The BD MAX™ GBS assay provides excellent clinical sensitivity (95.0%) and clinical specificity (96.7%) with an analytic sensitivity of only 200 cfu/ml.
Click Here to read more.
This will take effect December 2, 2013
Overview and Clinical Utility:
Effective December 2, 2013, PathGroup will implement in-house testing for Quantitative Kappa & Lambda Free light Chains, Serum. Measurements of free kappa and lambda light chains plays a key role in diagnosis, monitoring, and prognosis for many patients with a monoclonal gammopathy, and are an essential component of the primary screening algorithm for suspected monoclonal plasma cell disorders. Measurement of free light chains can aid in the diagnosis and monitoring of multiple myeloma, lymphocytic neoplasms, Waldenstrom’s macroglobulinemia, amyloid (AL) amyloidosis, and connective tissue diseases such as systemic lupus erythematosus (SLE) in conjunction with other laboratory and clinical findings.
Click Here to read more.
BRENTWOOD, Tenn. (December 3, 2013) – PathGroup, one of the largest private providers of pathology services in the United States, announced today that it has opened two new state-of-the-art facilities dedicated exclusively to molecular and cytology testing. The new laboratories are adjacent to PathGroup’s current laboratory at 658 Grassmere Park in Nashville, Tenn.
For Full Release, please CLICK HERE
This will take effect December 2, 2013
Overview and Clinical Utility:
Effective December 2, 2013, PathGroup will implement in-house testing for Serum Protein Electrophoresis (SPEP) and Immunofixation (IFE). Protein electrophoresis is a well-established technique routinely used for the screening of protein abnormalities. The fraction concentrations and the electrophoretic pattern may be characteristic of diseases such as monoclonal gammopathies, nephrotic syndrome, and inflammatory processes associated with infection, liver disease, and autoimmune diseases.
Click Here to read more.
This will take effect November 18, 2013
Overview and Clinical Utility:
Effective November 18, 2013, PathGroup will implement in-house Hemoglobin Evaluation testing utilizing agarose gel electrophoresis. Protein electrophoresis is a well-established technique routinely used for the screening of protein abnormalities. The resulting qualitative (or structural) abnormalities are called hemoglobinopathies. Additionally, decreased synthesis of one of the hemoglobin chains leads to quantitative (or regulation) abnormalities, called thalassemias.
Click Here to read more.
This will take effect November 18, 2013
Overview and Clinical Utility:
Effective November 18, 2013, PathGroup will implement in-house testing for Insulin-Like Growth Factor (IGF-1). IGF-1, also known as somatomedin C, is a 70 amino acid polypeptide produced primarily by the liver in response to endocrine growth hormone (GH) stimulus. Although partially responsible for systemic GH activities, it additionally contributes to anabolic, antioxidant, and cytoprotective functions.
Click Here to read more.
Overview and Clinical Utility:
When screening for Drugs of Abuse (DOA), or when monitoring patients taking prescription pain medications, the specimen of choice is urine as opposed to serum or plasma. Why Urine? Urine is considered the gold standard; it is non-invasive and fast. Samples are easy to collect and test and there is generally a longer window of detection than blood. Drugs of abuse can be detected in urine for days to weeks after exposure, in contrast to blood detection which is generally in hours. For example, heroin has a half-life of 6 to 15 minutes in blood, but opiate metabolites may be detected in urine for 2 to 3 days.
Click Here to read more.
This will take effect October 21, 2013
Overview and Clinical Utility:
Effective October 21, 2013, PathGroup will implement in-house testing for Beta-2-Microglobulin (B2M) Serum. B2M is a low molecular weight protein found on the surface of most nucleated cells. It forms the light chain component of the histocompatibility antigen and is eliminated via the kidneys. However, this is markedly increased in tubulo-interstitial disorders. Raised serum levels of B2M are associated with renal disease and rheumatoid arthritis. Elevated serum levels can also occur with systemic lupus erythematosus, malignant lymphoma and myeloma.
Click Here to read more.
Brentwood, Tenn.- (September 13, 2013) – PathGroup, one of the largest private providers of pathology services in the United States, announced today that it will begin offering Next-Generation Sequencing (NGS) and Cytogenomic Array (Array-Based Comparative Genomic Hybridization [aCGH]) for genetic profiling of cancer patients in late Q3 of this year. PathGroup’s SmartGenomics™ Profile will provide community-based oncologists with access to tests and data to make more precise, personalized therapeutic recommendations.
For Full Release, please CLICK HERE
Thomson Reuters, PathGroup and GenoSpace collaborate to deliver advanced personalized medicine assays and reports to oncologists
PHILADELPHIA, (August 13, 2013) — GenoSpace, PathGroup and the IP & Science business of Thomson Reuters today announced an innovative initiative to develop and deliver a best-in-class personalized medicine service in oncology, the result of which will enable physicians to make more precise therapeutic recommendations for cancer patients.
Click Here to read the full article.
